Yuanyuan Zhao

9PUBLICATIONS
38CO-AUTHORS
Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Jul 13, 2026
BCL-2/BCL-xL inhibitor pelcitoclax with osimertinib for EGFR-mutated advanced non-small-cell lung cancer: a phase 1b trial.

|May 05, 2026
Skeletal Muscle Metastasis in Patients With SMARCA4-Deficient Thoracic Tumors: A Retrospective Cohort Study.

|Mar 24, 2026
The Oncogenic EGFR-SHC1 Fusion Confers Insensitivity to EGFR-TKIs via Dual Activation of N-EGFR Kinase Domain and C-SHC1 Phosphorylation Sites in Lung Cancer.

Jiani Zheng, Shen Zhao, Jianhua Zhan

|Apr 22, 2025
Izalontamab (SI-B001), a Novel EGFRxHER3 Bispecific Antibody in Patients with Locally Advanced or Metastatic Epithelial Tumor: Results from First-in-Human Phase I/Ib Study.

Jinhui Xue, Yuxiang Ma, Yuanyuan Zhao

|Feb 26, 2025
A Novel Inflammation-Marker-Based Prognostic Model for Advanced Pulmonary Lymphoepithelioma-Like Carcinoma.

Xueyuan Chen, Tingting Liu, Silang Mo

|Jun 01, 2023
Phase I trial of KN046, a novel bispecific antibody targeting PD-L1 and CTLA-4 in patients with advanced solid tumors.

Yuxiang Ma, Jinhui Xue, Yuanyuan Zhao

Pageof 2

Frequent Collaborators

3 joint publications

Jinhui Xue

3 joint publications

Hongyun Zhao

3 joint publications

Yan Huang

2 joint publications

Yuxiang Ma